×
About 18,195 results

ALLMedicine™ B-cell Lymphoma Center

Research & Reviews  6,193 results

Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Folli...
https://doi.org/10.1016/j.clml.2021.12.010
Clinical Lymphoma, Myeloma & Leukemia; Palomba ML, Till BG et. al.

Jan 16th, 2022 - This was an open-label, phase 1b study assessing the safety, tolerability, preliminary efficacy and pharmacokinetics of the combination of atezolizumab and obinutuzumab in patients with relapsed/refractory follicular lymphoma (FL) or diffuse large...

Distinct clinical and genetic features of hepatitis B virus-associated follicular lymph...
https://doi.org/10.1182/bloodadvances.2021006410
Blood Advances; Ren W, Wang X et. al.

Jan 15th, 2022 - Hepatitis B virus (HBV) infection has been associated with an increased risk for B-cell lymphomas. We previously showed that 20% of diffuse large B-cell lymphoma (DLBCL) patients from China, an endemic area of HBV infection, have chronic HBV infec...

Indirect Comparison of Tisagenlecleucel and Historical Treatments for Relapsed/Refracto...
https://doi.org/10.1182/bloodadvances.2021006280
Blood Advances; Maziarz RT, Zhang J et. al.

Jan 15th, 2022 - No head-to-head trials have compared the efficacy of tisagenlecleucel versus historical treatments for adults with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). This study indirectly compared the overall survival (OS) and overa...

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-...
https://clinicaltrials.gov/ct2/show/NCT04980222

Jan 14th, 2022 - This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in individuals with circulating ...

Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathologi...
https://doi.org/10.3324/haematol.2021.279351
Haematologica Koch K, Richter J et. al.

Jan 14th, 2022 - The sole distinguishing feature of follicular lymphoma grade 3B and diffuse large B-cell lymphoma is the growth pattern assessed by histopathology analysis. Diffuse growth defines diffuse large B-cell lymphoma but the clinical relevance of this fi...

see more →

Guidelines  11 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

The management of primary mediastinal B-cell lymphoma: a British Society for Haematolog...
https://doi.org/10.1111/bjh.15731
British Journal of Haematology; Cwynarski K, Marzolini MAV et. al.

Jan 5th, 2019 - The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper.|2019|Cwynarski K,Marzolini MAV,Barrington SF,Follows G,Illidge T,|adverse effects,therapeutic use,chemically induced,diagnostic imaging,t...

Guidelines for the diagnosis and management of primary central nervous system diffuse l...
https://doi.org/10.1111/bjh.15661
British Journal of Haematology; Fox CP, Phillips EH et. al.

Nov 24th, 2018 - Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.|2018|Fox CP,Phillips EH,Smith J,Linton K,Gallop-Evans E,|diagnosis,therapy,diagnosis,therapy,

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lym...
https://doi.org/10.1016/j.ijrobp.2017.12.005
International Journal of Radiation Oncology, Biology, Phy... Ng AK, Yahalom J et. al.

Feb 8th, 2018 - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will s...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  264 results

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03571828

Jan 14th, 2022 - Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose [RP2D])

A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-...
https://clinicaltrials.gov/ct2/show/NCT04980222

Jan 14th, 2022 - This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in individuals with circulating ...

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
https://clinicaltrials.gov/ct2/show/NCT05192486

Jan 14th, 2022 - In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maxim...

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
https://clinicaltrials.gov/ct2/show/NCT05139017

Jan 13th, 2022 - The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL...

CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00924326

Jan 12th, 2022 - BACKGROUND: We have constructed a retroviral vector that encodes an anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) that recognizes the CD19 antigen. This chimeric receptor also contains the signaling domains of cluster o...

see more →

News  797 results

Rapid Readout: ZUMA‑7: Axicabtagene Ciloleucel versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B‐Cell Lymphoma
https://www.onclive.com/view/zuma-7-axicabtagene-ciloleucel-versus-standard-of-care-therapy-in-patients-with-relapsed-refractory-large-b-cell-lymphoma

Jan 13th, 2022 - OncLive® Rapid Readout from Primary Analysis of ZUMA‑7: a Phase 3 Randomized Trial of Axicabtagene Ciloleucel versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B‐Cell Lymphoma Segment Description: Frederick L. Locke, MD...

FDA Grants RMAT/Fast Track Designations to C-CAR039 for Relapsed/Refractory DLBCL
https://www.onclive.com/view/fda-grants-rmat-fast-track-designations-to-c-car039-for-relapsed-refractory-dlbcl

Jan 12th, 2022 - The FDA has granted a regenerative medicine advanced therapy (RMAT) designation and a fast track designation to C-CAR039 for use as a potential therapeutic option in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).1 A n...

Polatuzumab Vedotin Plus R-CHP Emerges as Potential New Standard for Newly Diagnosed DLBCL
https://www.onclive.com/view/polatuzumab-vedotin-plus-r-chp-emerges-as-potential-new-standard-for-newly-diagnosed-dlbcl

Jan 11th, 2022 - Polatuzumab vedotin-piiq (Polivy) plus rituximab (Rituxan), cyclophosphamide, doxorubicin, and prednisone (R-CHP; pola-R-CHP) showcased several benefits over R-CHOP (rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone...

Non-Hodgkin Lymphoma Updates From ASH 2021
https://www.mdedge.com/fedprac/article/250343/conference-recap/non-hodgkin-lymphoma-updates-ash-2021
Brad Kahl, MD

Jan 6th, 2022 - Brad Kahl, MD, shares results from non-Hodgkin lymphoma clinical trials that were presented at the 2021 American Society of Hematology (ASH) Annual Meeting. Dr Kahl looks first at a frontline study examining a new combination therapy.

Expansion Cohort Explores Efficacy of Novel Treatment for Waldenström Macroglobulinemia
https://www.onclive.com/view/expansion-cohort-explores-efficacy-of-novel-treatment-for-waldenstr-m-macroglobulinemia

Jan 5th, 2022 - Treatment options for patients with Waldeström macroglobulinemia (WM) are often derived from those developed for patients with multiple myeloma and other low-grade lymphomas. Patients with WM are relatively rare. Their disease is defined as lympho...

see more →

Patient Education  4 results see all →